Gilead's Yescarta puts pressure on BMS' Breyanzi with overall survival win in large B-cell lymphoma
A little less than a year after Gilead Sciences’ Yescarta broke new ground in blood cancer, the CAR-T therapy has hit on a gold standard for oncology meds. | Gilead's Yescarta has helped patients with large B-cell lymphoma live longer when used as a second-line treatment. The phase 3 update comes after a historic approval based on disease progression data.
What's Your Reaction?